Several hepatitis A outbreaks have occurred in recent years. Although vaccines exist, effective antivirals against hepatitis A virus (HAV) are lacking, and knowledge gaps remain regarding the viral replication cycle. Read More
A first-of-its-kind comprehensive map of the network of connections in the human immune system has uncovered previously unknown interactions and filled in gaps in understanding why approved immunotherapies work in some patients and not others. Read More
Gene expression profiles were retrieved from The Cancer Genomic Atlas lung adenocarcinoma (LUAD) cohort (TCGA - LAUD) (n = 567) and association of CYP4B1 with immune inhibitory components was analyzed to better understand the effect of this member of the CYP superfamily on LUAD immune microenvironment. Read More
Researchers developed three novel non-small cell lung cancer (NSCLC) patient-derived echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion cell lines, including CUTO8 (variant 1), 9 (variant 1) and 29 (variant 3), as well as a fourth ALK-positive cell line, YU1077 (EML4-ALK variant 3). Read More
Pfizer has patented isolated engineered immune cells expressing chimeric antigen receptors (CARs) comprising an epidermal growth factor receptor variant 3 (EGFRvIII) binding domain, a transmembrane domain and an intracellular signaling domain claimed to be potentially useful for the treatment of cancer. Read More
Immatics Biotechnologies has divulged immunogenic peptides claimed to be potentially useful as vaccines for the prevention and treatment of cancer. Read More
Thryv Therapeutics has presented new pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives acting as serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, Lafora disease and Parkinson's disease. Read More
AbbVie has patented cystic fibrosis transmembrane conductance regulator (CFTR) (deltaF508 mutant) correctors reported to be useful for the treatment of cystic fibrosis. Read More
Innovation Pharmaceuticals' brilacidin, a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus. Read More
To explore the role of histone deacetylase 11 (HDAC11) in Alzheimer's disease, Massachusetts General Hospital researchers generated selective, brain-penetrating HDAC11 inhibitors. Read More
